MITIGLINIDE CALCIUM DIHYDRATE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C19H24NO3.Ca.2H2O
Molecular Weight	704.906
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of MITIGLINIDE CALCIUM DIHYDRATE

SMILES

O.O.[Ca++].[O-]C(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)CC3=CC=CC=C3.[O-]C(=O)[C@H](CC(=O)N4C[C@H]5CCCC[C@H]5C4)CC6=CC=CC=C6

InChI

InChIKey=QEVLNUAVAONTEW-UZYHXJQGSA-L

InChI=1S/2C19H25NO3.Ca.2H2O/c2*21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14;;;/h2*1-3,6-7,15-17H,4-5,8-13H2,(H,22,23);;2*1H2/q;;+2;;/p-2/t2*15-,16+,17-;;;/m00.../s1

HIDE SMILES / InChI

Molecular Formula	Ca
Molecular Weight	40.078
Charge	2
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count	MOL RATIO 2 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C19H25NO3
Molecular Weight	315.4067
Charge	0
Count	MOL RATIO 2 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

Mitiglinide is a drug for the treatment of type 2 diabetes currently marked under tradename Glufast. Glufast® is available as the tablet for oral use, containing 5 mg or 10 mg of Mitiglinide calcium hydrate. The recommended dose is 10 mg three times daily just before each meal (within 5 minutes). Mitiglinide was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on January 29, 2004, and is currently co-marketed in Japan by Kissei and Takeda. Mitiglinide is a rapid-acting insulin secretion-stimulating agent, its belongs to the meglitinide (glinide) class of blood glucose-lowering drugs. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Kir6.2/SUR1 3	Inhibitor 8,504		4.0 nM [IC50]
Sulfonylurea receptor 2, Kir6.2 11	Inhibitor 8,504		3.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 262	Primary		Approved 8,583	Glufast

C_max

Value	Dose	Co-administered	Analyte	Population
683.2 μg/L	10 mg single, oral	Metformin	MITIGLINIDE plasma	Homo sapiens
704 μg/L	10 mg single, oral	Metformin	MITIGLINIDE plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
915.1 μg × h/L	10 mg single, oral	Metformin	MITIGLINIDE plasma	Homo sapiens
1025.5 μg × h/L	10 mg single, oral	Metformin	MITIGLINIDE plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.19 h	10 mg single, oral	Metformin	MITIGLINIDE plasma	Homo sapiens
2.67 h	10 mg single, oral	Metformin	MITIGLINIDE plasma	Homo sapiens

PubMed

Show entries

Title	Date	PubMed
Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel.	2001 Apr	11264248
Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs.	2001 Feb	11174074
Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent.	2001 Nov 23	11730726
Study of the insulinotropic effect of the novel antihyperglycemic agent KAD-1229 using HIT T15 cells, a hamster's insulinoma cell line.	2002	12236048
Effects of S 21403 on hormone secretion from isolated rat pancreas at different glucose concentrations.	2002 Dec 5	12450580

Showing 1 to 5 of 48 entries

Previous1 2 3 4 5…10Next

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is 10 mg three times daily just before each meal (within 5 minutes).

Route of Administration: Oral

In Vitro Use Guide

3T3-L1 cells were challenged during the first 4 days of differentiation with Mitiglinide at 1, 10 and 100 mkM. Seven days after the induction of 3T3-L1 cells, oil red O staining was used to detect triglyceride accumulation in 3T3-L1 cells.

Substance Class	Chemical
Record UNII	9651C21W3Z
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

MITIGLINIDE CALCIUM SALT DIHYDRATE

Preferred Name

English

MITIGLINIDE CALCIUM DIHYDRATE

Common Name

English

2H-ISOINDOLE-2-BUTANOIC ACID, OCTAHYDRO-.GAMMA.-OXO-.ALPHA.-(PHENYLMETHYL)-, CALCIUM SALT, HYDRATE (2:1:2), (.ALPHA.S,3AR,7AS)-

Common Name

English

MITIGLINIDE CALCIUM HYDRATE

Common Name

English

GLUFAST

Brand Name

English

Showing 1 to 5 of 12 entries

Previous1 2 3Next

Show entries

Code System

Code

Type

Description

DRUG BANK

DBSALT001868

PRIMARY

MERCK INDEX

m7566

PRIMARY

Merck Index

EPA CompTox

DTXSID5046728

PRIMARY

CAS

207844-01-7

PRIMARY

EVMPD

SUB21788

PRIMARY

Showing 1 to 5 of 8 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					P5WOR98G68

MITIGLINIDE CALCIUM ANHYDROUS

ANHYDROUS->SOLVATE


					D86I0XLB13

MITIGLINIDE

PARENT -> SALT/SOLVATE

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Related Record

Type

Details


					D86I0XLB13

MITIGLINIDE

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

PubMed

Patents

Sample Use Guides

C_max

T_1/2